On primary DCIS data, the COX2+P16+ Ki67+ classifier showed a significant OR for DCIS progression, while the onco-type DX DCIS showed a trend for predicting low-, intermediate-, or high-risk DCIS. This evidence concerns the gene MKI67 and ductal breast carcinoma in situ.